Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00061633 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Trial of TD 6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI)
A Phase 2 study of Burns and Ulcer, sponsored by Cumberland Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 169
- Enrollment target
- 1
- Study location
NCT00061633 is a Phase 2 study of Burns and Ulcer that has completed, run by Cumberland Pharmaceuticals. The registered enrollment target is 169 participants, above the 79-participant average among 36 other Burns trials with a reported enrollment target (114% higher). The trial reports 1 study location across 1 state.
The verdict
NCT00061633, a Phase 2 study of Burns and Ulcer, has completed, sponsored by Cumberland Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 169 participants
- Enrollment target
- 1
- Study location
Study Summary
Serious infections caused by resistant bacteria are becoming more of a medical problem throughout the world. One of the ways to deal with this problem is to develop new drugs that can control these bacteria. This study will measure how well TD-6424 (Telavancin) can control infections and whether this drug can be safely given to patients.
Conditions Studied
Interventions
- DRUG Telavancin
- DRUG Vancomycin or antistaphylococcal penicillin
Study Locations (1)
California
- eStudy Site, 3450 Bonita Road, Ste 201 - Chula Vista
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 169 participants |
| Start Date | 2003-06 |
| Est. Completion | 2004-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00061633
The ClinicalTrials.gov registry entry for NCT00061633 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 169 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 79-participant average among 36 other Burns trials with a reported enrollment target (114% higher). The listed sponsor is Cumberland Pharmaceuticals, which has 43 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Burns appearing as the primary indexed condition, and to 2 interventions - of which Telavancin is the first listed.
NCT00061633 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT00061633 about?
NCT00061633 is a clinical study titled "Phase 2 Trial of TD 6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI)". Serious infections caused by resistant bacteria are becoming more of a medical problem throughout the world. One of the ways to deal with this problem is to develop new drugs that can control these bacteria. This study will measure how well TD-6424 (Telavancin) can control infections and whether thi...
What is the current status of trial NCT00061633?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 169 participants. The study started on 2003-06. Estimated completion is 2004-01.
What conditions does trial NCT00061633 study?
This clinical trial studies the following conditions: Burns, Ulcer, Abscess, Cellulitis, Infections, Gram-positive Bacterial.
What interventions are being tested in trial NCT00061633?
The interventions under investigation include: Telavancin (DRUG), Vancomycin or antistaphylococcal penicillin (DRUG).
Who is sponsoring clinical trial NCT00061633?
This trial is sponsored by Cumberland Pharmaceuticals, which has 43 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00061633 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Burns
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
RECRUITING · Phase 2
-
4-Aminopyridine to Treat Skin Burns
RECRUITING · Phase 2
-
Cranial Electrotherapy Stimulation in Burned Patients
COMPLETED · Phase 2
-
VR for Burn Dressing Changes at Home
COMPLETED · Phase 2
-
Suprathel® Use During Prolonged Field Care to Promote Healing and Reduce the Need for Grafting of Burn Wounds
RECRUITING · NA
-
Liposomal Bupivacaine Versus Lidocaine for Skin Graft Donor Site Pain
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.